Transaction DateRecipientSharesTypePriceValue
8th October 2020Capital Management, L.P. Ra167,661Open or private sale$50.69$8,498,065.45
7th October 2020Capital Management, L.P. Ra98,597Open or private sale$50.95$5,023,527.01
30th September 2020Capital Management, L.P. Ra124,656Open or private sale$50.27$6,265,871.24
29th September 2020Capital Management, L.P. Ra80,707Open or private sale$52.08$4,202,986.51
29th September 2020Capital Management, L.P. Ra760,265Conversion of derivative$0.00
29th September 2020Capital Management, L.P. Ra950,000Open or private purchase$18.00$17,100,000.00
24th September 2020Capital Management, L.P. Ra473,327Open or private purchase$4.61$2,182,037.47
21st September 2020Capital Management, L.P. Ra2,145,045Conversion of derivative$0.00
21st September 2020Capital Management, L.P. Ra660,000Open or private purchase$19.00$12,540,000.00
17th September 2020Capital Management, L.P. Ra1,300,000Open or private purchase$28.00$36,400,000.00
Verastem logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Verastem, Inc. is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K)

Ticker: VSTM
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1526119
Employees: 169
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $125 M (0%)
Inventory, Net: $6 M (0%)
Assets, Current: $145 M (70%)
Property, Plant and Equipment, Net: $791 Th (-16%)
Other Assets, Noncurrent: $401 Th (-50%)
Assets: $199 M (36%)
Accounts Payable, Current: $2 M (-76%)
Accrued Liabilities, Current: $21 M (0%)
Liabilities, Current: $29 M (-3%)
Other Liabilities, Noncurrent: $870 Th (0%)
Liabilities: $84 M (-38%)
Common Stock, Value, Issued: $17 Th (112%)
Common Stock, Shares, Issued: $169 M (211260%)
Additional Paid in Capital, Common Stock: $700 M (31%)
Retained Earnings (Accumulated Deficit): $586 M (0%)
Stockholders' Equity (Parent): $114 M (0%)
Liabilities and Equity: $199 M (36%)
Revenue: $4 M (-53%)
Research and Development: $9 M (-53%)
Operating Income/Loss: $21 M (-55%)